Abstract
Of 25 dapsone derivatives and analogs screened for activity against Mycobacterium leprae in the mouse footpad system, only 7 were active. All seven were metabolized to or contaminated with dapsone.
Full text
PDF![791](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfba/352553/97857409c6a9/aac00293-0155.png)
![792](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfba/352553/c398ab74eeda/aac00293-0156.png)
![793](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfba/352553/20634d088dfe/aac00293-0157.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BRODIE B. B., GILLETTE J. R., LA DU B. N. Enzymatic metabolism of drugs and other foreign compounds. Annu Rev Biochem. 1958;27(3):427–454. doi: 10.1146/annurev.bi.27.070158.002235. [DOI] [PubMed] [Google Scholar]
- Ellard G. A. Absorption, metabolism and excretion of di(rho-aminophenyl) sulphone (dapsone) and di(rho-aminophenyl) sulphoxide in man. Br J Pharmacol Chemother. 1966 Jan;26(1):212–217. doi: 10.1111/j.1476-5381.1966.tb01823.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ellard G. A., Gammon P. T., Rees R. J. The minimal inhibitory concentrations of sulphadimethozine and sulphadoxine against Mycobacterium leprae. Lepr Rev. 1970 Oct;41(4):223–228. doi: 10.5935/0305-7518.19700031. [DOI] [PubMed] [Google Scholar]
- Gaugas J. M. Antimicrobial therapy of experimental human leprosy (Myco. leprae) infection in the mouse foot pad. Lepr Rev. 1967 Oct;38(4):225–230. doi: 10.5935/0305-7518.19670037. [DOI] [PubMed] [Google Scholar]
- Gleason L. N., Vogh B. P. Deformylation of 4,4'-diformamidodiphenyl sulfone (DFD) by plasma of certain mammals. Biochem Pharmacol. 1971 Sep;20(9):2409–2416. doi: 10.1016/0006-2952(71)90241-3. [DOI] [PubMed] [Google Scholar]
- KARLSON A. G. THE IN VIRTO ACTIVITY OF 4,4'-DIAMINODIPHENYL SULFONE AGAINST VARIOUS ACID-FAST MICROORGANISMS. Int J Lepr. 1963 Apr-Jun;31:183–187. [PubMed] [Google Scholar]
- Levy L., Biggs J. T., Jr, Gordon G. R., Peters J. H. Disposition of the antileprosy drug, dapsone, in the mouse. Proc Soc Exp Biol Med. 1972 Jul;140(3):937–943. doi: 10.3181/00379727-140-36584. [DOI] [PubMed] [Google Scholar]
- Ozawa T., Shepard C. C., Karat A. B. Application of spectrophotofluorometric procedures to some problems in Mycobacterium leprae infections in mice and man treated with dapsone (DDS), diacetyl-DDS (DADDS), and di-formyl-DDS (DFD). Am J Trop Med Hyg. 1971 Mar;20(2):274–281. doi: 10.4269/ajtmh.1971.20.274. [DOI] [PubMed] [Google Scholar]
- Panitch M., Levy L. The action of dapsone on a susceptible strain of Mycobacterium kansasii. Lepr Rev. 1978 Jun;49(2):131–140. doi: 10.5935/0305-7518.19780016. [DOI] [PubMed] [Google Scholar]
- Pattyn S. R., van Ermengem J. DDS sensitivity of mycobacteria. Antagonistic effect of PABA for M. ulcerans and M. kansasii. Int J Lepr Other Mycobact Dis. 1968 Oct-Dec;36(4):427–431. [PubMed] [Google Scholar]
- Peters J. H., Gordon G. R., Murray J. F., Jr, Fieldsteel A. H., Levy L. Minimal inhibitory concentration of dapsone for Mycobacterium leprae in rats. Antimicrob Agents Chemother. 1975 Nov;8(5):551–557. doi: 10.1128/aac.8.5.551. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rees R. J. Recent bacteriologic, immunologic and pathologic studies on experimental human leprosy in the mouse foot pad. Int J Lepr. 1965 Jul-Sep;33(3 Suppl):646–657. [PubMed] [Google Scholar]
- Shepard C. C. Activity of repository sulfones against Mycobacterium leprae in mice. Proc Soc Exp Biol Med. 1967 Feb;124(2):430–433. doi: 10.3181/00379727-124-31757. [DOI] [PubMed] [Google Scholar]
- Shepard C. C. Further experience with the kinetic method for the study of drugs against Mycobacterium leprae in mice. Activities of DDS, DFD, ethionamide, capreomycin and PAM 1392. Int J Lepr Other Mycobact Dis. 1969 Oct-Dec;37(4):389–397. [PubMed] [Google Scholar]
- Shepard C. C., McRae D. H. A method for counting acid-fast bacteria. Int J Lepr Other Mycobact Dis. 1968 Jan-Mar;36(1):78–82. [PubMed] [Google Scholar]